Smart nanoparticles for cancer therapy
- PMID: 37919282
- PMCID: PMC10622502
- DOI: 10.1038/s41392-023-01642-x
Smart nanoparticles for cancer therapy
Abstract
Smart nanoparticles, which can respond to biological cues or be guided by them, are emerging as a promising drug delivery platform for precise cancer treatment. The field of oncology, nanotechnology, and biomedicine has witnessed rapid progress, leading to innovative developments in smart nanoparticles for safer and more effective cancer therapy. In this review, we will highlight recent advancements in smart nanoparticles, including polymeric nanoparticles, dendrimers, micelles, liposomes, protein nanoparticles, cell membrane nanoparticles, mesoporous silica nanoparticles, gold nanoparticles, iron oxide nanoparticles, quantum dots, carbon nanotubes, black phosphorus, MOF nanoparticles, and others. We will focus on their classification, structures, synthesis, and intelligent features. These smart nanoparticles possess the ability to respond to various external and internal stimuli, such as enzymes, pH, temperature, optics, and magnetism, making them intelligent systems. Additionally, this review will explore the latest studies on tumor targeting by functionalizing the surfaces of smart nanoparticles with tumor-specific ligands like antibodies, peptides, transferrin, and folic acid. We will also summarize different types of drug delivery options, including small molecules, peptides, proteins, nucleic acids, and even living cells, for their potential use in cancer therapy. While the potential of smart nanoparticles is promising, we will also acknowledge the challenges and clinical prospects associated with their use. Finally, we will propose a blueprint that involves the use of artificial intelligence-powered nanoparticles in cancer treatment applications. By harnessing the potential of smart nanoparticles, this review aims to usher in a new era of precise and personalized cancer therapy, providing patients with individualized treatment options.
© 2023. The Author(s).
Conflict of interest statement
The authors declare no competing interests. L.C. is an editorial board member of the Signal Transmission and Targeted Therapy.
Figures





References
-
- Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J. Clin. 2021;71:209–249. - PubMed
-
- Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J. Clin. 2018;68:394–424. - PubMed
-
- Messinger YH, et al. Bortezomib combined with VXLD chemotherapy is highly effective in advanced B-lineage acute lymphoblastic leukemia allowing early study termination due to efficacy. A Therapeutic Advances in Childhood Leukemia (TACL) Consortium Phase II Study. Blood. 2011;118:251. doi: 10.1182/blood.V118.21.251.251. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical